Penumbra sales rise 16% on thrombectomy growth; no full-year guidance

Penumbra Inc. (PEN) reported third-quarter revenue of $410.1 million, up 15.6% from a year earlier, according to a press release furnished with an 8-K filed Oct. 29. The figure was in line with the $407.38 million revenue estimate compiled by Finnhub.

The company said it will not provide financial guidance for the full year 2026 and will not host a conference call. It cited the pending acquisition of Penumbra by Boston Scientific Corporation (NYSE: BSX).

Here's how the company did:

• Revenue: $410.1 million vs. $354.7 million a year earlier, in line with the $407.38 million expected, according to Finnhub
• Diluted EPS: $1.07 vs. $1.17 a year earlier
• Net income: $42.3 million vs. $45.9 million a year earlier
• Income from operations: $50.7 million vs. $48.8 million a year earlier

The company develops technologies for ischemic stroke, venous thromboembolism and acute limb ischemia. It said it supports healthcare providers in more than 100 countries.

Segment results

Thrombectomy revenue rose 18.1% to $279.2 million. U.S. VTE revenue increased 26.0% from the same period a year ago.

Embolization and access revenue rose 10.8% to $131.0 million. U.S. neuro revenue was $77.9 million, up 19.3%.

By geography, United States revenue was $324.2 million, up 17.9%. International revenue was $85.9 million, up 7.8%.

For the first nine months of 2026, revenue was $1.17 billion, up 15.4% from $1.02 billion a year earlier, according to the release's year-to-date table.

Costs and margin

Gross profit margin was 68.3%, an increase of 0.5% from a year earlier.

Sales, general and administrative expenses were $204.2 million. That figure includes $7.1 million of acquisition-related expenses tied to the pending Boston Scientific deal. Research and development expenses were $25.4 million.

Guidance and outlook

The company will not give full-year 2026 financial guidance, and the release does not include a forecast for the next period.